Bellicum announces presentation by unc at ash 2022 on potential abrogation of ic9 car t-cell toxicities with rimiducid

Houston, dec. 11, 2022 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the university of north carolina lineberger comprehensive cancer center (unc lineberger) team at the 64th american society of hematology (ash) annual meeting and exposition being held in new orleans december 10-13, 2022. the presentation, scheduled for today at 6 p.m. ct, will provide data on four patients who received rimiducid to activate the caspacide® safety switch in an investigator sponsored trial.
BLCM Ratings Summary
BLCM Quant Ranking